肿瘤细胞治疗研究
英文原题：More T cell receptors to the RAScue in cancer?
使用经基因工程改造以表达肿瘤反应性 T 细胞受体（TCR）的 T 细胞进行的治疗，即 TCR 基因治疗（TCR-T），是一种对肿瘤患者有前景的免疫治疗手段。
利用经基因工程改造、表达肿瘤反应性T细胞受体（TCR）的T细胞进行治疗，即TCR基因疗法（TCR-T），是癌症患者一种有前景的免疫治疗方法。选择最佳TCR和靶向肿瘤抗原是TCR-T治疗的关键考量。本期《临床研究杂志》（JCI）中，Bear及其同事报告使用体外实验对4种TCR进行表征；这些TCR可识别致癌性KRAS G12V突变，并受HLA-A*03:01或HLA-A*11:01限制。TCR来源于健康供者，或曾接受突变KRAS疫苗接种的胰腺癌患者。最有前景的TCR值得在KRAS G12V阳性癌症患者中开展测试。
Treatment with T cells genetically engineered to express tumor-reactive T cell receptors (TCRs), known as TCR-gene therapy (TCR-T), is a promising immunotherapeutic approach for patients with cancer. The identification of optimal TCRs to use and tumor antigens to target are key considerations for TCR-T. In this issue of the JCI, Bear and colleagues report on their use of in vitro assays to characterize four HLA-A*03:01- or HLA-A*11:01-restricted TCRs targeting the oncogenic KRAS G12V mutation. The TCRs were derived from healthy donors or patients with pancreatic cancer who had received a vaccine against mutant KRAS. The most promising TCRs warrant testing in patients with KRAS G12V-positive cancers.
MEMBER ACCOUNT
登录成功会直接打开下一页。
